Olema Pharmaceuticals, Inc. (OLMA) NASDAQ
10.69
-2.02(-15.89%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
10.69
-2.02(-15.89%)
Currency In USD
| Previous Close | 12.71 |
| Open | 12.43 |
| Day High | 12.61 |
| Day Low | 10.66 |
| 52-Week High | 36.26 |
| 52-Week Low | 3.89 |
| Volume | 2.74M |
| Average Volume | 1.48M |
| Market Cap | 933.74M |
| PE | -5.27 |
| EPS | -2.03 |
| Moving Average 50 Days | 14.67 |
| Moving Average 200 Days | 16.77 |
| Change | -2.02 |
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 19, 2026 9:30 PM GMT
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies
Olema Oncology Announces Departure of Chief Operating and Financial Officer
GlobeNewswire Inc.
Jan 30, 2026 9:01 PM GMT
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies